Less Ads, More Data, More Tools Register for FREE

Pin to quick picksExperian Regulatory News (EXPN)

Share Price Information for Experian (EXPN)

Share Price is delayed by 15 minutes
Get Live Data
2,617.00    9.00 (0.35%)
Bid:
2,619.00
Ask:
2,620.00
Spread: 1.00 (0.038%)
Market Cap: £23.19b
EXPN Live PriceLast checked at - London Stock Exchange

Intraday Experian Share Chart

Director/PDMR Shareholding

13 Mar 2025 17:38

RNS Number : 6343A
Experian plc
13 March 2025
 

Experian plc

 

 

Director/PDMR Shareholding

 

 

13 March 2025 - Experian plc, the global data and technology company, (the "Company"), hereby notifies the market that it has received the following individual notification relating to a purchase of shares by Kathleen DeRose, a non-executive director of the Company.

 

The notification was made under article 19.1 of the UK Market Abuse Regulation ('MAR'). This announcement is made in accordance with Article 19.3 of MAR.

 

 

1 - Details of the person discharging managerial responsibilities / person closely associated

 

 

 

Natural Person

Kathleen DeRose

 

 

2 - Reason for the notification

 

 

 

Position/status

Non-executive director

 

 

Initial notification / Amendment

Initial Notification

 

 

3 - Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

 

 

Full name of the entity

Experian plc

Legal Entity Identifier code

635400RXXHHYT1JTSZ26

 

 

 

4 - Details of the transaction(s)

 

 

 

 

Description of the financial instrument, type of instrument

 

Ordinary shares of US 10 cents each in Experian plc

 

Identification Code

GB00B19NLV48

 

 

Nature of transaction

Purchase of Ordinary Shares (EXPGF)

 

 

Currency

USD

 

 

Prices(s) and volumes(s)

Price

Volume

$45.532

400

 

 

Aggregated Information

Price

Volume

$45.532

400

 

 

Date of Transaction

 

2025-03-13

 

 

Place of transaction

US OTC

 

 

 

 

 

 

 

 

 

Contact:

 

Experian

Charles Brown Company Secretary +353 (0) 86 819 4473

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money.

 

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

 

We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 22,500 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUMWWUPAGMW
Date   Source Headline
17th May 202311:00 amRNSShare repurchases
17th May 20237:00 amRNSFull-year financial report
28th Apr 202310:15 amRNSTotal Voting Rights
12th Apr 20239:30 amRNSAdditional Listing
4th Apr 20239:45 amRNSAdditional Listing
31st Mar 202311:35 amRNSTotal Voting Rights
29th Mar 20239:20 amRNSAdditional Listing
28th Mar 20237:00 amRNSDirectorate Change
22nd Mar 20235:19 pmRNSTransaction in Own Shares
22nd Mar 20239:15 amRNSAdditional Listing
20th Mar 20235:18 pmRNSTransaction in Own Shares
17th Mar 20235:31 pmRNSTransaction in Own Shares
16th Mar 20235:09 pmRNSTransaction in Own Shares
16th Mar 20239:15 amRNSBlock listing Interim Review
15th Mar 20235:14 pmRNSTransaction in Own Shares
15th Mar 20239:15 amRNSAdditional Listing
14th Mar 20235:21 pmRNSTransaction in Own Shares
13th Mar 20235:31 pmRNSTransaction in Own Shares
10th Mar 20236:10 pmRNSTransaction in Own Shares
9th Mar 20235:22 pmRNSTransaction in Own Shares
8th Mar 20235:21 pmRNSTransaction in Own Shares
8th Mar 20239:15 amRNSAdditional Listing
7th Mar 20235:26 pmRNSTransaction in Own Shares
1st Mar 202312:00 pmRNSDirector/PDMR Shareholding
1st Mar 20239:15 amRNSAdditional Listing
28th Feb 202312:20 pmRNSTotal Voting Rights
22nd Feb 202310:00 amRNSAdditional Listing
15th Feb 202310:45 amRNSAdditional Listing
10th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20239:30 amRNSAdditional Listing
1st Feb 20239:15 amRNSAdditional Listing
31st Jan 20232:30 pmRNSDirector Declaration
31st Jan 202310:15 amRNSTotal Voting Rights
25th Jan 20239:15 amRNSAdditional Listing
17th Jan 20237:00 amRNSExperian Q3 FY23 trading update
13th Jan 20235:20 pmRNSFirst interim dividend
9th Jan 20237:00 amRNSDirectorate Change
30th Dec 202210:15 amRNSTotal Voting Rights
16th Dec 202211:30 amRNSElections for first interim dividend
14th Dec 20229:15 amRNSAdditional Listing
7th Dec 20229:00 amRNSAdditional Listing
30th Nov 202211:59 amRNSTotal Voting Rights
16th Nov 20227:00 amRNSHalf-year Report
31st Oct 20229:30 amRNSTotal Voting Rights
14th Oct 20229:51 amRNSShare Repurchase Programme
6th Oct 20227:00 amRNSDirectorate Change
5th Oct 20229:10 amRNSAdditional Listing
30th Sep 202212:06 pmRNSTotal Voting Rights
28th Sep 20229:02 amRNSAdditional Listing
19th Sep 202210:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.